Carbon capture and sequestration (CCS) technology is advancing, and possible applications range from enhancing recovery of oil to mitigating effects of climate change. There are three general options for carbon capture being pursued; currently, postcombustion capture is the most highly developed option. The reader is referred to an

Forthcoming in Xiangming Chen and Huang Jianfu, eds. Global Aspirations/Local

For policy analysts, knowledge about the values and opinions of the actors involved in a decision making situation are more important than knowledge about the factors in such a situation. Finding out how actors perceive a situation, or – to be more realistic – reflecting on the consequences

With the signing of the CUSFTA, the NAFTA and the GATT agreement there are

Abstract. Economic cost-benefit analysis is used by environmental pol-icy analysts as a primary tool for assessing policy efficacy. Economists often stress that cost-benefit analysis is simply a calculation method, and not a guide to appropriate action. However, as cost-benefit analysis is used

i Acknowledgments This study was commissioned by The Nature Conservancy, and funded by a grant from the David and Lucile Packard Foundation. We appreciate the advice, guidance, and input provided by TNC staff and Verde Valley community members who served on the study’s advisory group:

Introduction. This paper briefly describes the oil and gas sector’s practice of hydraulic fracturing for the Western Interstate Energy Board. Interestingly, although public interest in this practice is relatively recent, its use by the oil and gas sector dates back to the late 1940s. The paper includes the following sections: importance of unconventional gas reservoirs, technical aspects of hydraulic fracturing, regulation of hydraulic fracturing,

with interleukin-2, the only medication approved by the Food and Drug Administration (FDA) at the time to treat her disease. When that treatment failed, her father began researching investigational medications, learning in 2004 that both Pfizer and Bayer were conducting clinical trials for new investigational medications to treat kidney cancer. Karnes was ineligible for the clinical trial because her cancer had previously spread to her brain. Although her brain tumors had been removed, she was still disqualified from joining the clinical trial, so her father sought expanded access for his daughter. Months passed before he was able to secure access for his daughter. He contacted Congressman Dan Burton’s (R-IN) office for assistance, and drew media coverage of Karnes ’ struggle in the Wall Street Journal. On March 24, 2005, the FDA notified the family that it had approved a single-patient IND for Karnes. Tragically, it was too late—Kianna Karnes died the same day access was approved.2 Less than a year later, both drugs were given final FDA approval to treat advanced kidney cancer. Speaking after his daughter’s death, her father said, “I don’t know that either of these drugs would have saved Kianna’s life, but wouldn’t it be nice to give her a chance?”3 In the case of Kianna Karnes, she had a better chance than most patients at receiving expanded access. As her father explained, “Here is a case where her old man understood clinical trials. I knew about compassionate use; I had a friendship with a powerful member of Congress; I’ve got the Wall Street Journal behind me. But I still couldn’t save

location of birth.

Organized by Instituut voor de Overheid American Society for Public Administration